Triple therapy for treating type 2 diabetes (NICE TA418)
Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
The LSCMMG recommends dapagliflozin as a 1st line ““gliflozin””.
Reason for decision:
Suitable for initiation in primary care